Claire Roddie
About
Claire Roddie is a scholar working on Oncology, Immunology and Molecular Biology.
According to data from OpenAlex, Claire Roddie has authored 74 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Oncology, 17 papers in Immunology and 15 papers in Molecular Biology. Recurrent topics in Claire Roddie's work include CAR-T cell therapy research (58 papers), Acute Lymphoblastic Leukemia research (11 papers) and Advancements in Semiconductor Devices and Circuit Design (10 papers). Claire Roddie is often cited by papers focused on CAR-T cell therapy research (58 papers), Acute Lymphoblastic Leukemia research (11 papers) and Advancements in Semiconductor Devices and Circuit Design (10 papers). Claire Roddie collaborates with scholars based in United Kingdom, United States and Spain. Claire Roddie's co-authors include Karl S. Peggs, Welby Montalvo-Ortiz, Tyler R. Simpson, Jeffrey V. Ravetch, Fubin Li, Manuel A. Sepúlveda, Frederick Arce, Jedd D. Wolchok, Hideo Yagita∥ and James P. Allison and has published in prestigious journals such as Journal of Clinical Investigation, The Journal of Experimental Medicine and Journal of Clinical Oncology.
In The Last Decade
Claire Roddie
65 papers receiving 2.1k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Claire Roddie United Kingdom | 17 | 1.6k | 1.0k | 336 | 220 | 190 | 74 | 2.2k | ||
| Dina Schneider United States | 20 | 1.2k 0.8× | 815 0.8× | 502 1.5× | 372 1.7× | 414 2.2× | 67 | 2.0k | ||
| Sandra H. Thomas United States | 25 | 978 0.6× | 409 0.4× | 351 1.0× | 202 0.9× | 152 0.8× | 60 | 1.9k | ||
| Tessa Kerre Belgium | 26 | 769 0.5× | 940 0.9× | 670 2.0× | 214 1.0× | 147 0.8× | 112 | 2.1k | ||
| Lazaros J. Lekakis United States | 22 | 1.1k 0.7× | 339 0.3× | 305 0.9× | 223 1.0× | 144 0.8× | 101 | 1.6k | ||
| Maria Teresa Lupo Stanghellini Italy | 20 | 1.5k 0.9× | 998 1.0× | 606 1.8× | 583 2.6× | 357 1.9× | 76 | 2.5k | ||
| Sarah Nikiforow United States | 31 | 1.8k 1.1× | 1.4k 1.4× | 463 1.4× | 310 1.4× | 255 1.3× | 152 | 3.4k | ||
| Tanja Lövgren Sweden | 16 | 608 0.4× | 1.1k 1.1× | 281 0.8× | 241 1.1× | 87 0.5× | 30 | 1.7k | ||
| Rammurti T. Kamble United States | 17 | 1.4k 0.9× | 514 0.5× | 545 1.6× | 508 2.3× | 360 1.9× | 66 | 2.1k | ||
| Reuben Benjamin United Kingdom | 19 | 498 0.3× | 295 0.3× | 374 1.1× | 252 1.1× | 112 0.6× | 43 | 1.1k | ||
| Alana A. Kennedy‐Nasser United States | 13 | 1.3k 0.8× | 757 0.7× | 517 1.5× | 669 3.0× | 277 1.5× | 23 | 2.1k |
Countries citing papers authored by Claire Roddie
Since
Specialization
Citations
This map shows the geographic impact of Claire Roddie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claire Roddie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claire Roddie more than expected).
Fields of papers citing papers by Claire Roddie
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Claire Roddie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claire Roddie. The network helps show where Claire Roddie may publish in the future.
Co-authorship network of co-authors of Claire Roddie
This figure shows the co-authorship network connecting the top 25 collaborators of Claire Roddie. A scholar is included among the top collaborators of Claire Roddie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claire Roddie. Claire Roddie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Park, Jae H., Paul Shaughnessy, Aaron C. Logan, et al.. (2025). Deep Molecular Remission Predicts Better Clinical Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) Treated with Obecabtagene Autoleucel (obe-cel). Transplantation and Cellular Therapy. 31(2). S216–S217.
2.
Vonberg, Frederick W., Imran Malik, Maeve O’Reilly, et al.. (2025). Neurotoxic complications of chimeric antigen receptor (CAR) T-cell therapy. Journal of Neurology Neurosurgery & Psychiatry. 96(7). 665–678.
3.
Cwynarski, Kate, et al.. (2025). CAR‐T Cell Therapy for PTLD: Analysis of CAR‐T Product, Engraftment, and Outcomes in Patients Receiving Parallel Immunosuppression. eJHaem. 6(1). e70006–e70006.
4.
Dias, Juliana, et al.. (2024). CAR-T cell manufacturing landscape—Lessons from the past decade and considerations for early clinical development. Molecular Therapy — Methods & Clinical Development. 32(2). 101250–101250.
5.
Park, Jae H., Paul Shaughnessy, Aaron C. Logan, et al.. (2024). Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Deep Molecular Remission May Predict Better Outcomes. Blood. 144(Supplement 1). 963–963.
6.
Marzolini, Maria A. V., Irfan Kayani, Ben Carpenter, et al.. (2024). The Effect of the Pre‐Transplant Disease Status on the Outcome for Recipients of T‐Cell Depleted Allogeneic Haematopoietic Stem Cell Transplants for Large B Cell Lymphomas. European Journal Of Haematology. 114(3). 545–555.
7.
O’Reilly, Maeve, Lorna Neill, Simon M. Collin, et al.. (2024). High pretreatment disease burden as a risk factor for infectious complications following CD19 chimeric antigen receptor T‐cell therapy for large B‐cell lymphoma. HemaSphere. 8(1). e29–e29.
8.
O’Reilly, Maeve, et al.. (2024). Malnutrition and cachexia are associated with poor CAR T-cell therapy outcomes including survival. Clinical Nutrition ESPEN. 62. 206–215.
9.
Rampotas, Alexandros, Johanna Richter, David Isenberg, & Claire Roddie. (2024). CAR-T cell therapy embarks on autoimmune disease. Bone Marrow Transplantation. 60(1). 6–9.
10.
Shah, Bijal, Jeremy Pantin, Karamjeet Sandhu, et al.. (2024). Healthcare Resource Utilization and Costs Associated with Managing CRS and ICANS in Patients with Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia Receiving Obecabtagene autoleucel (obe-cel). Blood. 144(Supplement 1). 4837–4837.
11.
Chen, Daniel, Maeve O’Reilly, Ryan Low, et al.. (2024). CD19‐targeting chimeric antigen receptor T‐cell therapy is safe and effective for intra‐cardiac B cell non‐Hodgkin lymphoma. SHILAP Revista de lepidopterología. 5(6). 1283–1289.
12.
Mekkaoui, Leila, Christopher Allen, Jasmine Huang, et al.. (2023). Large-scale manufacturing of base-edited chimeric antigen receptor T cells. Molecular Therapy — Methods & Clinical Development. 31. 101123–101123.
13.
Nastoupil, Loretta J., Manali Kamdar, Julio C. Chávez, et al.. (2023). LISOCABTAGENE MARALEUCEL (LISO‐CEL) VERSUS STANDARD OF CARE (SOC) AS SECOND‐LINE THERAPY IN LARGE B‐CELL LYMPHOMA (TRANSFORM STUDY): SUBGROUP ANALYSES BY PRIOR THERAPY RESPONSE. Hematological Oncology. 41(S2). 212–214.
14.
Hoelzer, D., Renato Bassan, Nicolas Boissel, et al.. (2023). ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia. Annals of Oncology. 35(1). 15–28.
15.
Roddie, Claire, Lorna Neill, Wendy Osborne, et al.. (2023). Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma. Blood Advances. 7(12). 2872–2883.
16.
Vargas, Frederick Arce, Claire Roddie, Paul Shaughnessy, et al.. (2022). Industrialization of an Academic Miltenyi Prodigy-Based CAR T Process. Transplantation and Cellular Therapy. 28(3). S201–S202.
17.
Mullanfiroze, Khushnuma, Arina Lazareva, Jan Chu, et al.. (2022). CD34+-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy. Blood Advances. 6(16). 4715–4718.
18.
Shafat, Manar, Harpreet Hyare, Lorna Neill, et al.. (2021). Pembrolizumab for the treatment of progressive multifocal leukoencephalopathy following anti‐CD19 CAR‐T therapy: a case report. SHILAP Revista de lepidopterología. 2(4). 848–853.
19.
Marzolini, Maria A. V., Lorna Neill, Maeve O’Reilly, Karl S. Peggs, & Claire Roddie. (2021). Lymphocyte morphology in a patient receiving CD19 chimeric antigen receptor T‐cell therapy for mantle cell lymphoma. SHILAP Revista de lepidopterología. 3(1). 245–246.
20.
Simpson, Tyler R., Fubin Li, Welby Montalvo-Ortiz, et al.. (2013). Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma. The Journal of Experimental Medicine. 210(9). 1695–1710.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Dina Schneider Breakdown of academic impact, for papers by Sandra H. Thomas Breakdown of academic impact, for papers by Tessa Kerre Breakdown of academic impact, for papers by Lazaros J. Lekakis Breakdown of academic impact, for papers by Maria Teresa Lupo Stanghellini Breakdown of academic impact, for papers by Sarah Nikiforow Breakdown of academic impact, for papers by Tanja Lövgren Breakdown of academic impact, for papers by Rammurti T. Kamble Breakdown of academic impact, for papers by Reuben Benjamin Breakdown of academic impact, for papers by Alana A. Kennedy‐Nasser